Aliskiren: Review of efficacy and safety data with focus on past and recent clinical trials

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 5, 2013, Pages 232-241

  Şen, Selçuk ^a   Sabırlı, Soner ^a   Özyiğit, Tolga ^a   Üresin, Yağız ^a  

^a Department of Pharmacology ^*  (Turkey)

Author keywords

Aliskiren; Hypertension; Renin inhibitor

Indexed keywords

ALISKIREN; AMLODIPINE; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; VALSARTAN;

ANGIONEUROTIC EDEMA; ASTHENIA; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA;

EID: 84888414622     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313495288     Document Type: Article

References (40)

1. Alderman M. Madhavan S. Ooi W. Cohen H. Sealey J. Laragh J. (1991) Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098–1104.
2. Alderman M. Ooi W. Cohen H. Madhavan S. Sealey J. Laragh J. (1997) Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 10: 1–8.
3. Andersen K. Weinberger M. Egan B. Constance C. Ali M. Jin J. et al. (2008) Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double blind trial. J Hypertens 26: 589–599.
4. Azizi M. Webb R. Nussberger J. Hollenberg N. (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24: 243–256.
5. Blumenstein M. Romaszko J. Calderon A. Andersen K. Ibram G. Liu Z. et al. (2009) Antihypertensive efficacy and tolerability of aliskiren / hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 25: 903–910.
6. Brown M. McInnes G. Papst C. Zhang J. MacDonald M. (2011) Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 377: 312–320.
7. Chobanian A. Bakris G. Black H. Cushman W. Green L. Izzo J. Jr et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252.
8. Cohn J. Tognoni G. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675.
9. Duprez D. Davis P. Botha J. (2008) The AGELESS study: the effect of aliskiren versus ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients 65 years of age with systolic hypertension. Circulation 118: 886–887.
10. Duprez D. Munger M. Botha J. Keefe D. Charney A. (2010) Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 24: 600–608.
11. Frampton J. Curran M. (2007) Aliskiren: a review of its use in the management of hypertension. Drugs 67: 1767–1792.
12. Gheorghiade M. Böhm M. Greene S. Fonarow G. Lewis E. Zannad F. et al. (2013). Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309: 1125–1135.
13. Gradman A. Schmieder R. Lins R. Nussberger J. Chiang Y. Bedigian M. (2005) Antihypertensive aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111: 1012–1018.
14. Gradman A. Traub D. (2007) The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovascular Med 8: 22–30.
15. Harel Z. Gilbert G. Wald R. Bell C. Perl J. Juurlink D. et al. (2012) The effect of combination treatment with aliskiren and blockers of the renin–angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 344: e42.
16. Krum H. Massie B. Abraham W. Dickstein K. Kober L. McMurray J. et al. (2011) Direct renin inhibition in addition to or as an alternative to angiotensinconverting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 13: 107–114.
17. Mancia G. de Backer G. Dominiczak A. Cifkova R. Fagard R. Germano G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105–1187.
18. Mann J. Schmieder R. McQueen M. Dyal L. Schumacher H. Pogue J. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553.
19. McMurray J. Abraham W. Dickstein K. Køber L. Massie B. Krum H. (2012) Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 14: 341–343.
20. McMurray J. Östergren J. Swedberg K. Granger C. Held P. Michelson E. et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771.
21. McMurray J. Pitt B. Latini R. Maggioni A. Solomon S. Keefe D. et al. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1: 17–24.
22. Nakamura T. Sato E. Amaha M. Kawagoe Y. Maeda S. Yamagishi S. (2011) Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst 13: 122-127.
23. Nakao N. Yoshimura A. Morita H. Takada M. Kayano T. Ideura T. (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117–124.
24. Nickenig G. Simanenkov V. Lembo G. Rodriguez P. Salko T. Ritter S. et al. (2008) Efficacy of aliskiren / hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press 2: 31–40.
25. Oparil S. Yarows S. Patel S. Fang H. Zhang J. Satlin A. (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221–229.
26. Palatini P. Jung W. Shlyakhto E. Botha J. Bush C. Keefe D. (2010) Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 24: 93–103.
27. Parving H. Brenner B. McMurray J. Zeeuw D. Haffner S. Solomon S. et al. (2009) Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663–1671.
28. Parving H. Persson F. Lewis J. Lewis E. Hollenberg N. (2008) AVOID study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433–2446.
29. Pool J. Schmieder R. Azizi M. Aldigier J. Januszewicz A. Zidek W. et al. (2007) Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 20: 11–20.
30. Schmieder R. Philipp T. Guerediaga J. Gorostidi M. Smith B. Weissbach N. et al. (2009) Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 119: 417–425.
31. Scirica B. Morrow D. Bode C. Ruzyllo W. Ruda M. Ophuis A. et al. (2010) Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43, Trial. Eur Heart J 31: 1993–2005.
32. Solomon S. Appelbaum E. Manning W. Verma A. Berglund T. Lukashevich V. (2009) Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119: 530–537.
33. Solomon S. Sung H. Shah A. Skali H. Desai A. Kober L. et al. (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 32: 1227–1234.
34. Stanton A. Dicker P. O'Brien E. (2009) Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens 22: 954–957.
35. Turnbull F. (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 362: 1527–1535.
36. Uresin Y. Taylor A. Kilo C. Tschöpe D. Santonastaso M. Ibram G. et al. (2007) Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8: 190–198.
37. Verdecchia P. Angeli F. Mazzotta G. Martire P. Garofoli M. Gentile G. et al. (2010) Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 4: 193–200.
38. Villamil A. Chrysant S. Calhoun D. Schober B. Hsu H. Matrisciano-Dimichino L. et al. (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25: 217–226.
39. White W. Bresalier R. Kaplan A. Palmer B. Riddell R. Lesogor A. et al. (2010) Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich) 12: 765–775.
40. White W. Bresalier R. Kaplan A. Palmer B. Riddell R. Lesogor A. et al. (2011) Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich) 13: 506–516.